Search Result

Results for "

CDK2 activity

" in MedChemExpress (MCE) Product Catalog:

By Targets:	AAK1 (1) Akt (2) Anaplastic lymphoma kinase (ALK) (2) Apoptosis (22) Aurora Kinase (1) Bacterial (1) c-Kit (1) Carbonic Anhydrase (3) Casein Kinase (1) Caspase (1) CDK (61) Checkpoint Kinase (Chk) (1) Cholinesterase (ChE) (1) COX (1) CXCR (2) Cyclin G-associated Kinase (GAK) (1) DNA/RNA Synthesis (1) EGFR (3) Endogenous Metabolite (1) Enterovirus (1) ERK (1) FLT3 (1) GSK-3 (5) HDAC (2) JAK (2) LIM Kinase (LIMK) (1) MDM-2/p53 (1) MEK (2) Microtubule/Tubulin (1) Mitochondrial Metabolism (1) Molecular Glues (1) Necroptosis (1) PARP (1) Phosphatase (1) PI3K (3) Pim (1) PKC (4) PROTACs (1) Reactive Oxygen Species (2) Salt-inducible Kinase (SIK) (1) SphK (1) Trk Receptor (1) VEGFR (3) Wee1 (1)
By Research Areas:	Cancer (68) Infection (1) Inflammation/Immunology (3) Neurological Disease (4)

By Targets:

AAK1 (1)

Akt (2)

Anaplastic lymphoma kinase (ALK) (2)

Apoptosis (22)

Aurora Kinase (1)

Bacterial (1)

c-Kit (1)

Carbonic Anhydrase (3)

Casein Kinase (1)

Caspase (1)

CDK (61)

Checkpoint Kinase (Chk) (1)

Cholinesterase (ChE) (1)

COX (1)

CXCR (2)

Cyclin G-associated Kinase (GAK) (1)

DNA/RNA Synthesis (1)

EGFR (3)

Endogenous Metabolite (1)

Enterovirus (1)

ERK (1)

FLT3 (1)

GSK-3 (5)

HDAC (2)

JAK (2)

LIM Kinase (LIMK) (1)

MDM-2/p53 (1)

MEK (2)

Microtubule/Tubulin (1)

Mitochondrial Metabolism (1)

Molecular Glues (1)

Necroptosis (1)

PARP (1)

Phosphatase (1)

PI3K (3)

Pim (1)

PKC (4)

PROTACs (1)

Reactive Oxygen Species (2)

Salt-inducible Kinase (SIK) (1)

SphK (1)

Trk Receptor (1)

VEGFR (3)

Wee1 (1)

By Research Areas:

Cancer (68)

Infection (1)

Inflammation/Immunology (3)

Neurological Disease (4)

Inhibitors & Agonists

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-130001

CDK9-IN-9	CDK	Cancer
CDK9-IN-9 (example 2) is a potent and selective *CDK9* inhibitor with an IC₅₀ of 1.8 nM. CDK9-IN-9 inhibits CDK2 with an IC₅₀ of 155 nM. CDK9-IN-9 has anti-cancer activity .

HY-144810

CDK2-IN-8	CDK	Cancer
CDK2-IN-8 is a potent *CDK2* inhibitor with an IC₅₀ of 1.74 µM. CDK2-IN-8 shows antiproliferative activity. CDK2-IN-8 has the potential for the research of melanoma .

HY-144811

CDK2-IN-9	CDK Apoptosis	Cancer
CDK2-IN-9 is a potent *CDK2* inhibitor with an IC₅₀ of 0.63 µM. CDK2-IN-9 shows antiproliferative activity. CDK2-IN-9 induces apoptosis and cell cycle arrest at S and G2/M phase. CDK2-IN-9 has the potential for the research of melanoma .

HY-170441

CDK2-IN-36	CDK	Cancer
CDK2-IN-36 (compound1) is a *CDK2* inhibitor with anticancer activity .

HY-163357

CDK2/MDM2-IN-1	CDK MDM-2/p53	Cancer
CDK2/MDM2-IN-1 (III-13) is a dual inhibitor of CDK2/MDM2 with an IC₅₀ value of 2.60 nM for CDK2. CDK2/MDM2-IN-1 has antitumor activity .

HY-155966

CDK2-IN-19	CDK	Cancer
CDK2-IN-19 (Compound 32) is a selective and orally active *CDK2* inhibitor (K_i: 0.18 nM). CDK2-IN-19 shows anticancer activity in mice bearing OVCAR3 tumors .

HY-170442

CDK2-IN-37	CDK	Cancer
CDK2-IN-37 (COMPOUND 2) is a cyclin-dependent kinase *(CDK2)* inhibitor with anti-cancer activity .

HY-150573

CDK2-IN-12	CDK Carbonic Anhydrase	Cancer
CDK2-IN-12 (compound 10b) is a potent *CDK2* inhibitor, with an IC₅₀ of 11.6 μM. CDK2-IN-12 inhibits hCA (carbonic anhydrase) isoforms I, II, IX and XII, with K_I values of 3534, 638.4, 44.3, and 48.8 nM. CDK2-IN-12 shows anticancer activity .

HY-164827

CDK2 degrader 3	CDK	Cancer
CDK2 degrader 3 can selectively degrade *CDK2* and has anti-tumor activity .

HY-172153

CDK2-IN-41	CDK Reactive Oxygen Species Apoptosis	Cancer
CDK2-IN-41 (Compound 7a) is a *CDK2* inhibitor that exerts anticancer activity by binding to *CDK2, thereby inhibiting the cell cycle, inducing cytotoxicity, promoting ROS* production, and triggering Apoptosis. CDK2-IN-41 exhibits an IC₅₀ of 10 µM against acute myeloid leukemia (AML) HL-60 cells. It holds potential for research in AML-related cancer therapy .

HY-143497

HDAC1/2 and CDK2-IN-1	HDAC CDK Apoptosis	Cancer
HDAC1/2 and CDK2-IN-1 (compound 14d) is a potent HDAC1, HDAC2 and *CDK2* dual inhibitor, with IC₅₀ values of 70.7, 23.1 and 0.80 μM, respectively. HDAC1/2 and CDK2-IN-1 can block the cell cycle and induce apoptosis. HDAC1/2 and CDK2-IN-1 exhibits desirable in vivo antitumor activity .

HY-168845

CDK2/9-IN-1	CDK Apoptosis	Cancer
CDK2/9-IN-1 (compound 20a) is an orally active dual inhibitor of *CDK2* and *CDK9* with IC₅₀ values are 0.004 μM and 0.009 μM respectively. CDK2/9-IN-1 induces apoptosis by regulating G2/M cell cycle arrest. CDK2/9-IN-1 has antitumor activity .

HY-123045

PNU-292137	CDK	Cancer
PNU-292137 is an orally active, potent *CDK2* inhibitor with IC₅₀s of 37 nM and 92 nM for CDK2/cyclin A and CDK2/cyclin E, respectively. PNU-292137 makes interactions with the hydrophobic pocket at the back of the CDK2 ATP pocket. PNU-292137 efficiently inhibits tumor cell proliferation in human colon and prostate tumor cell lines. PNU-292137 exhibits antitumor activity (TGI>50%) in a mouse xenograft model .

HY-15004

AUZ 454 5 Publications Verification K03861	CDK	Cancer
AUZ 454 (K03861) is a type II *CDK2* inhibitor with K_d of 8.2 nM. AUZ 454 (K03861) inhibits CDK2 activity by competing with binding of activating cyclins.

HY-120497

PKCζ-IN-1	PKC CDK	Cancer
PKCζ-IN-1 is a compound that inhibits PKCζ and CDK2, showing an IC50 value of 5.18 nM for PKCζ and 1.04 μM for CDK2, with significant selectivity of 200-fold. PKCζ-IN-1 can reduce the activity of CDK2 while inhibiting PKCζ.

HY-173147

CDK2-IN-42	CDK	Cancer
CDK2-IN-42 (Compound H63) is a *CDK12* inhibitor with an IC₅₀ value of 10 nM. CDK2-IN-42 has anti-ESCC (Esophageal Squamous Cell Carcinoma) cell activity. It can block transcriptional elongation, downregulate the core genes in the G1 phase to induce cell cycle arrest, and alter the CDK12-ATM/ATR-CHEK1/CHEK2 signaling axis, resulting in DNA damage. CDK2-IN-42 can effectively inhibit tumor growth in a xenograft mouse model of human ESCC KYSE150. CDK2-IN-42 holds great promise for research in the field of cancer .

HY-12843

Bohemine 1 Publications Verification	CDK ERK	Cancer
Bohemine is a purine analogue and is a synthetic and selective *CDK* inhibitor with IC₅₀s of 4.6 μM, 83 μM, and 2.7 μM for Cdk2/cyclin E, Cdk2/cyclin A, and Cdk9/cyclin T1, respectively. Bohemine also inhibits ERK2 with an IC₅₀ of 52 μM and has less inhibitory effect on CDK1, CDK4 and CDK6. Bohemine has a broad spectrum anti-cancer activities .

HY-111932

Indirubin-5-sulfonate	CDK GSK-3	Cancer
Indirubin-5-sulfonate is a cyclin-dependent kinase (CDK) inhibitor, with IC₅₀ values of 55 nM, 35 nM, 150 nM, 300 nM and 65 nM for CDK1/cyclin B, CDK2/cyclin A, CDK2/cyclin E, CDK4/cyclin D1, and CDK5/p35, respectively . Indirubin-5-sulfonate also shows inhibitory activity against GSK-3β .

HY-W011428

Olomoucine	CDK	Others Cancer
Olomoucine is an ATP competitive inhibitor of *CDKs. Olomoucine is a purine (HY-34431) derivative and inhibits CDC2/cyclin B, Cdk2/cyclin A, Cdk2/cyclin E (both IC₅₀=7 μM), CDK/p35 kinase (IC₅₀=3 μM) and ERK1/p44 MAP kinase (IC₅₀=25 μM) . Olomoucine regulates cell cycle and shows anti-melanin tumor activity* .

HY-115943

Anticancer agent 30	CDK	Cancer
Anticancer agent 30 (compound 6f-Z), a 3-arylidene-2-oxindole derivative, is a selective *CDK2* inhibitor with potent anticancer activity .

HY-108359

Alsterpaullone 1 Publications Verification 9-Nitropaullone; NSC 705701	CDK GSK-3 Apoptosis	Cancer
Alsterpaullone (9-Nitropaullone) is a potent *CDK* inhibitor, with IC₅₀s of 35 nM, 15 nM, 200 nM and 40 nM for CDK1/cyclin B, CDK2/cyclin A, CDK2/cyclin E and *CDK5/p35, respectively. Alsterpaullone also competes with ATP for binding to GSK-3alpha/GSK-3beta with IC₅₀s of both 4 nM. Alsterpaullone has antitumor activity, and possesses potential for the study in neurodegenerative and proliferative disorders . Alsterpaullone induces apoptosis* in leukemia cell line .

HY-153221

QR-6401	CDK	Cancer
QR-6401 is an orally active and selective macrocyclic *CDK2* inhibitor with IC₅₀ values of 0.37, 10, 22, 34 and 45 nM for *CDK2/E1, CDK9/T1, CDK1/A2, CDK6/D3* and *CDK4/D1, respectively. QR-6401 has potent antitumor activity* in an OVCAR3 ovarian cancer xenograft model. QR-6401 has the potential to be used in the study of cancer .

HY-170507

CDK-IN-16	CDK	Cancer
CDK-IN-16 (Compound 5g) is a CDK2/cyclin A2 inhibitor with an IC₅₀ of 1.67 μM. CDK-IN-16 exhibits anticancer activity. The IC₅₀ of CDK-IN-16 against the AGS cell line is 3.5 μM .

HY-112358

GW8510	CDK	Neurological Disease Cancer
GW8510 is a potent cyclin-dependent kinase-2 (CDK2) inhibitor. GW8510 is also a ribonucleotide reductase M2 (RRM2) inhibitor. GW8510 exhibits neuroprotective and anticancer activities .

HY-137894A

Tagtociclib hydrate PF-07104091 hydrate	CDK GSK-3	Cancer
PF-07104091 hydrate is a potent and selective CDK2/cyclin E₁ and GSK3β inhibitor, with K_is of 1.16 and 537.81 nM, respectively. PF-07104091 hydrate has anti-tumor activity for cyclin E₁-amplified cancers. (patent WO2020157652A2).

HY-162683

(S)-PHA533533	CDK	Neurological Disease Cancer
(S)-PHA533533 is a cyclin-dependent kinase 2 (CDK2) inhibitor. (S)-PHA533533 shows anti-tumor activity and can induce widespread neuronal UBE3A expression in angelman syndrome model mice .

HY-151436

ZLMT-12	CDK Cholinesterase (ChE) Apoptosis	Cancer
ZLMT-12 (compound 35), tacrine derivatives, is a potent, orally active *CDK2/9* inhibitor with IC₅₀ values of 0.002 and 0.011 μM for CDK9 and CDK2, respectively. ZLMT-12 has a weak inhibitory effect on AChE (IC₅₀=19.023 μM) and BChE (IC₅₀=2.768 μM). ZLMT-12 has low toxicity and antiproliferative activity. ZLMT-12 induces apoptosis and arrests the cell cycle in the S phase and G2/M phase .

HY-132914

CDK/HDAC-IN-1	CDK	Cancer
CDK/HDAC-IN-1 shows remarkable *CDK2/4/6* and HDAC6 inhibitory activity of IC₅₀ = 60.9 ± 2.9, 276 ± 22.3, 27.2 ± 4.2, and 128.6 ± 0.4 nM, respectively.

HY-162528

CDK12-IN-7	CDK	Cancer
CDK12-IN-7 (Compound 2) is a *CDK12* and *CDK2* inhibitor with IC₅₀ values of 42 and 196 nM, respectively. CDK12-IN-7 has anti-cell proliferation activity and can be used in cancer research .

HY-19316

NU2058 O6-(Cyclohexylmethyl)guanine	CDK	Cancer
NU2058 (O6-(Cyclohexylmethyl)guanine) is a potent, competitive and guanine-based *CDK* inhibitor with IC₅₀s of 17 μM and 26 μM for CDK2 and CDK1. NU2058 has anti-cancer activity.

HY-N5072

Desmethylglycitein 1 Publications Verification 4',6,7-Trihydroxyisoflavone	CDK PI3K PKC	Cancer
Desmethylglycitein (4',6,7-Trihydroxyisoflavone), a metabolite of daidzein, sourced from Glycine max with antioxidant, and anti-cancer activities. Desmethylglycitein binds directly to *CDK1* and *CDK2* in vivo, resulting in the suppresses CDK1 and CDK2 activity . Desmethylglycitein is a direct inhibitor of protein kinase C (PKC)α, against solar UV (sUV)-induced matrix matrix metalloproteinase 1 (MMP1) . Desmethylglycitein binds to PI3K in an ATP competitive manner in the cytosol, where it inhibits the activity of PI3K and downstream signaling cascades, leading to the suppression of adipogenesis in 3T3-L1 preadipocytes .

HY-118310

Xylocydine	CDK	Cancer
Xylocydine is an inhibitor of *CDK1/2, inhibiting CDK* function in various apoptotic processes. Xylocydine specifically blocks CDK1 and CDK2 activity with IC50 of 1.4 nM and 61 nM, respectively. In addition, Xylocydine downregulates phosphorylated nucleolin and retinoblastoma protein levels. .

HY-114177

Ebvaciclib 3 Publications Verification PF-06873600	CDK	Cancer
PF-06873600 is a selective and orally bioavailable inhibitor of cyclin-dependent kinase *(CDK), with K_i* values of 0.09 nM, 0.13 nM and 0.16 nM for CDK2, CDK4 and CDK6, respectively. PF-06873600 has potential antineoplastic activity .

HY-111361

FN-1501 1 Publications Verification LT-171-861	CDK FLT3	Cancer
FN-1501 is a potent inhibitor of FLT3 and *CDK, with IC₅₀s of 2.47, 0.85, 1.96, and 0.28 nM for CDK2/cyclin A, CDK4/cyclin D1, CDK6/cyclin D1 and FLT3, respectively. FN-1501 has anticancer activity*.

HY-168067

CDK-IN-14	CDK Caspase Apoptosis	Cancer
CDK-IN-14 (B34) is a *CDK2* inhibitor (IC₅₀=0.097 μM) with anti-hepatocellular carcinoma activity. CDK-IN-14 blocks the cell cycle of HepG-2 cancer cells through a caspase-mediated mechanism and induces apoptosis .

HY-107419

NU6140 1 Publications Verification	CDK Aurora Kinase	Cancer
NU6140 is a selective CDK2-cyclin A inhibitor (IC₅₀, 0.41 μM), exhibits 10- to 36-fold selectivity over other CDKs . NU6140 also potently inhibits Aurora A and Aurora B, with IC₅₀s of 67 and 35 nM, respectively . Enhances the apoptotic effect, with anti-cancer activity .

HY-10012

AZD-5438 10+ Cited Publications	CDK	Cancer
AZD-5438 is a potent *CDK1, CDK2, and CDK9* inhibitor, with IC₅₀s of 16 nM, 6 nM, and 20 nM in cell-free assays, respectively. AZD-5438 shows less inhibition activity against GSK3β, CDK5 and CDK6 .

HY-163566

Apoptosis inducer 18	Apoptosis	Cancer
Apoptosis inducer 18, a potent inducer of apoptosis, shows significant cytotoxicity to the breast cancer cell line MCF-7 (IC₅₀=0.559 μM). Apoptosis inducer 18 inhibits cell cycle progression and promotes apoptosis by binding to DNA and causing damage, and by binding to the active site of *CDK-2, interfering with its kinase activity*. Apoptosis inducer 18 can be used in anti-breast cancer research .

HY-112450

Olomoucine II	CDK	Cancer
Olomoucine II is a potent *CDK* inhibitor with IC₅₀ values of 0.06, 0.1, 0.45, 7.6, 19.8 µM for CDK9/cyclin T, CDK2/cyclin E, CDK7/cyclin H, CDK1/cyclin B, CDK4/cyclin D1, respectively. Olomoucine II shows antiproliferative activity .

HY-163856

CDK7-IN-30	Apoptosis CDK	Cancer
CDK7-IN-30 (Compound 22) is a *CDK7* inhibitor (IC₅₀ = 7.21 nM) that effectively inhibits the phosphorylation of RNA Polymerase II and *CDK2. CDK7-IN-30 CDK7-IN-30 can induce cell apoptosis* and has anti-cancer activity and can be used in cancer research .

HY-15491

AG-024322	COX Apoptosis	Cancer
AG-024322 is a potent ATP-competitive pan-CDK inhibitor against cell cycle kinases *CDK1, CDK2, and CDK4* with K_i values in the 1-3 nM range . AG-024322 displays broad-spectrum anti-tumor activity and clear target modulation in vivo. AG-024322 induces cell apoptosis .

HY-114302

CCB02 1 Publications Verification	Microtubule/Tubulin	Cancer
CCB02 is a selective CPAP-tubulin interaction inhibitor, binding to tubulin and competing for the CPAP binding site of β-tubulin, with an IC₅₀ of 689 nM, and shows potent anti-tumor activity. CCB02 shows no inhibition on the cell cycle- and centrosome-related kinases, or the phosphorylation status of Aurora A, Plk1, Plk2, CDK2, and CHK1 .

HY-132578

M5N36	Phosphatase	Cancer
M5N36 is a potent and selective Cdc25C inhibitor with IC₅₀ values of 0.15, 0.19, 0.06 µM for Cdc25A, Cdc25B, Cdc25C, respectively. M5N36 shows anti-proliferative activity and increases the expression of p-CDK1 and p-CDK2 .

HY-12214A

NVP-2 Maximum Cited Publications 34 Publications Verification	CDK Apoptosis	Cancer
NVP-2 is a potent and selective ATP-competitive cyclin dependent kinase 9 (CDK9) probe, inhibits CDK9/CycT activity with an IC₅₀ of 0.514 nM. NVP-2 displays inhibitory effcts on CDK1/CycB, CDK2/CycA and CDK16/CycY kinases with IC₅₀ values of 0.584 µM, 0.706 µM, and 0.605 µM, respectively. NVP-2 induces cell apoptosis.

HY-150570

Carbonic anhydrase inhibitor 14	Carbonic Anhydrase CDK	Cancer
Carbonic anhydrase inhibitor 14 (Compound 8b) is a carbonic anhydrase (CA) inhibitor with K_i values of 1203, 99.7, 9.4 and 27.7 nM against hCA I, hCA II, hCA IX and hCA XII, respectively. Carbonic anhydrase inhibitor 14 can also inhibit *CDK2* with an IC₅₀ of 20.3 μM. Carbonic anhydrase inhibitor 14 shows antitumor activity .

HY-169296

IMPDH2-IN-4	VEGFR CDK	Cancer
IMPDH2-IN-4 (compound 2d), a Mycophenolic acid (HY-B0421) analogue, is a selective IMPDH2 inhibitor with a K_i of 1.8 μM. IMPDH2-IN-4 exhibits good cytotoxic activity against osteosarcoma cancer cell lines. IMPDH2-IN-4 possesses a high affinity for VEGFR-2, CDK2, and IMPDH .

HY-138293

SY-5609 1 Publications Verification CDK7-IN-3	CDK Apoptosis	Cancer
SY-5609 (CDK7-IN-3) is an orally active, highly selective, noncovalent *CDK7* inhibitor with a K_D of 0.065 nM. SY-5609 shows poor inhibition on CDK2 (K_i=2600 nM), CDK9 (K_i=960 nM), CDK12 (K_i=870 nM). SY-5609 induces apoptosis in tumor cells and has antitumor activity .

HY-151071

TMX-3013	CDK	Cancer
TMX-3013 is a *CDKs* inhibitor capable of inhibiting the activity of *CDK1, CDK2, CDK4, CDK5, and CDK6, with IC₅₀* values of 0.9 nM, <0.5 nM, 24.5 nM, 0.5 nM, and 15.6 nM, respectively. TMX-3013 can be utilized for synthesizing PROTACs that feature a polyethylene glycol (PEG) linker arm and Thalidomide (HY-14658) as the CRBN-recruiting arm .

HY-13650

Indisulam 10+ Cited Publications E 7070	Molecular Glues Carbonic Anhydrase	Cancer
Indisulam (E 7070) is a carbonic anhydrase inhibitor with anticancer activity. Indisulam (E 7070) is a sulfonamide agent that targets the G1 phase of the cell cycle. Indisulam (E 7070) causes a blockade in the G1/S transition through inhibition of the activation of both *CDK2* and cyclin E. Indisulam (E 7070) targets splicing by inducing RBM39 degradation via recruitment to DCAF15 .

HY-119016

SK1-I 1 Publications Verification BML-258	SphK	Cancer
SK1-I (BML-258), an analog of sphingosine, is an isozyme-specific competitive SPHK1 inhibitor with a K_i value of 10 µM . SK1-I shows no activity at SPHK1 PKCα, PKCδ, PKA, AKT1, ERK1, EGFR, CDK2, IKKβ or CamK2β. SK1-I enhances autophagy and has antitumor activity .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

CDK2 activity

Inhibitors & Agonists

NaturalProducts

Natural
Products